共 50 条
- [21] Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancerNature Cancer, 2022, 3 : 927 - 931Laura M. SpringHyo HanMinetta C. LiuErika HamiltonHanna IrieCesar A. Santa-MariaJames ReevesPeng PanMing ShanYongqiang TangJulie R. GrahamSebastien HazardLeif W. EllisenSteven J. Isakoff
- [22] OlympiAD final overall survival: Olaparib versus chemotherapy treatment of physician's choice (TPC) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)CANCER RESEARCH, 2018, 78 (13)Robson, Mark E.Im, Seock-AhSenkus, ElzbietaXu, BingheDomchek, SusanMasuda, NorikazuDelaloge, SuzetteLi, WeiTung, NadineArmstrong, AnneWu, WentingGoessl, CarstenRunswick, SarahConte, Pierfranco
- [23] OlympiaN: a phase 2, multicenter, open-label study to assess the efficacy and safety of neoadjuvant olaparib monotherapy and olaparib plus durvalumab in patients with BRCA mutations and early-stage HER2-negative breast cancerCANCER RESEARCH, 2023, 83 (05)Balmana, JudithDymond, MikeLowe, Elizabeth S.Lukashchuk, NataliaWinter, MariaTung, Nadine
- [24] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysisANNALS OF ONCOLOGY, 2022, 33 : S205 - S206Balmana, J.Fasching, P. A.Delaloge, S.Park, Y. H.Eisen, A.Bourgeois, H.Kemp, Z.Jankowski, T.Sohn, J.Aksoy, S.Timcheva, C. V.Park-Simon, T-W.Torres, A. AntonJohn, E.Baria, K.Walker, G.Gelmon, K. A.
- [25] Olaparib plus /- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trialCANCER RESEARCH, 2023, 83 (08)Fanucci, Kristina A.Pilat, Mary JoShyr, DerekShyr, YuBoerner, Scott A.Durecki, DianeNoonan, AnneAbramson, VandanaSanta-Maria, CesarHan, HyoNanda, RitaDees, Elizabeth ClairePark, HaeseongBuys, SaundraPeswani, NamrataChew, HelenAssad, HadeelWulf, GerburgRichardson, AngeliqueTrivedi, Meghna S.Brufsky, AdamAbbruzzese, JamesAfghahi, AnoshehSharon, EladSchalper, KurtLoRusso, Patricia
- [26] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCYBreast Cancer Research and Treatment, 2024, 204 : 237 - 248Judith BalmañaPeter A. FaschingFergus J. CouchSuzette DelalogeIntidhar Labidi-GalyJoyce O’ShaughnessyYeon Hee ParkAndrea F. EisenBenoit YouHughes BourgeoisAnthony GonçalvesZoe KempAngela SwampillaiTomasz JankowskiJoo Hyuk SohnElena PoddubskayaGuzel MukhametshinaSercan AksoyConstanta V. TimchevaTjoung-Won Park-SimonAntonio Antón-TorresEllie JohnKatherine BariaIsabel GibsonKaren A. Gelmon
- [27] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCYBREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (02) : 237 - 248Balmana, JudithFasching, Peter A.Couch, Fergus J.Delaloge, SuzetteLabidi-Galy, IntidharO'Shaughnessy, JoycePark, Yeon HeeEisen, Andrea F.You, BenoitBourgeois, HughesGoncalves, AnthonyKemp, ZoeSwampillai, AngelaJankowski, TomaszSohn, Joo HyukPoddubskaya, ElenaMukhametshina, GuzelAksoy, SercanTimcheva, Constanta V.Park-Simon, Tjoung-WonAnton-Torres, AntonioJohn, EllieBaria, KatherineGibson, IsabelGelmon, Karen A.Koynova, TatyanaPopov, VasilTimcheva, ConstantaTomova, AntoanetaEisen, AndreaGelmon, KarenLemieux, JulieAugereau, PauleBazan, FernandoBecuwe, CeliaBourgeois, HuguesChakiba, CamilleChehimi, MohamadCheneau, CarolineDalenc, Florencede Guillebon, Eleonorede la Motte Rouge, ThibaultFrenel, Jean-SebastienGoncalves, AnthonyGrenier, JulienHardy-Bessard, Anne ClaireLamy, RegineLevy, ChristelleLortholary, AlainMailliez, Audrey
- [28] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II studyBREAST CANCER RESEARCH AND TREATMENT, 2022, 197 (3) : 489 - 501Xu, BingheSun, TaoShi, YanxiaCui, JiuweiYin, YongmeiOuyang, QuchangLiu, QiangZhang, QingyuanChen, YidingWang, ShoumanWang, XiaojiaTong, ZhongshengZhong, YahuaWang, JiayuYan, MinYan, XiWang, ChuanFeng, JifengWang, XiuliHu, GangCheng, YingGe, RuiminZhu, ZhaoyinZhang, WaShao, Zhimin
- [29] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II studyBreast Cancer Research and Treatment, 2023, 197 : 489 - 501Binghe XuTao SunYanxia ShiJiuwei CuiYongmei YinQuchang OuyangQiang LiuQingyuan ZhangYiding ChenShouman WangXiaojia WangZhongsheng TongYahua ZhongJiayu WangMin YanXi YanChuan WangJifeng FengXiuli WangGang HuYing ChengRuimin GeZhaoyin ZhuWa ZhangZhimin Shao
- [30] Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancerANNALS OF ONCOLOGY, 2022, 33 (07) : S788 - S789Banerjee, S.Imbimbo, M.Roxburgh, P.Kim, J-W.Kim, M. H.Plummer, R.Stemmer, S.You, B.Ferguson, M.Penson, R. T.O'Malley, D.Meyer, K.Gao, H.Angell, H.Nunes, A. TablanteDomchek, S.Drew, Y.